| Product NDC: | 51079-213 |
| Proprietary Name: | Cilostazol |
| Non Proprietary Name: | cilostazol |
| Active Ingredient(s): | 100 mg/1 & nbsp; cilostazol |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 51079-213 |
| Labeler Name: | UDL Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077323 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20110623 |
| Package NDC: | 51079-213-20 |
| Package Description: | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-213-20) > 1 TABLET in 1 BLISTER PACK (51079-213-01) |
| NDC Code | 51079-213-20 |
| Proprietary Name | Cilostazol |
| Package Description | 100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-213-20) > 1 TABLET in 1 BLISTER PACK (51079-213-01) |
| Product NDC | 51079-213 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | cilostazol |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20110623 |
| Marketing Category Name | ANDA |
| Labeler Name | UDL Laboratories, Inc. |
| Substance Name | CILOSTAZOL |
| Strength Number | 100 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Phosphodiesterase 3 Inhibitor [EPC],Phosphodiesterase 3 Inhibitors [MoA] |